Business
Distribution Agreement with MANUS Neurodynamica
Distribution Agreement with MANUS Neurodynamica.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 8855B Cambridge Cognition Holdings PLC 22 June 2016 \n\n22 June 2016\n \nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\n \nDistribution agreement with MANUS Neurodynamica\n \nThe neuroscience technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets products and technologies for near-patient cognitive assessment, has entered into a distribution agreement with UK healthcare technology company MANUS Neurodynamica Limited.\nThe agreement provides Cambridge Cognition with sole rights to market the MANUS Parkinson's Pen, a sensor pen for diagnosis and monitoring of neuromotor impairments, in academic research, pharmaceutical clinical trials and occupational health markets. The CE Class I medical device uses non-invasive, patented technology to record and analyse limb and hand motion to assess underlying neuromotor processes, particularly for patients with Parkinson's disease.\nAn estimated seven to 10 million people worldwide are living with Parkinson's disease, which is predicted to more than double by the year 2040.1 The combined direct and indirect cost of Parkinson's is estimated to be nearly $25 billion per year in the United States alone.2\nEarly diagnosis and timely access to specialist care for patients is essential. However, current diagnostic methods for Parkinson's disease are based on a clinician's subjective interpretation or neuroimaging techniques, which are expensive, invasive and require skilled operators. The Parkinson's pen will provide an easy to use, non-invasive alternative.\nFollowing completion of final product enhancements, Cambridge Cognition expects to begin marketing the product initially for use in academic research through its existing global sales channels in Q4 2016. The product will subsequently be marketed for use by healthcare professionals to improve the certainty of differential diagnosis; in pre-symptomatic screening to identify and triage patients at risk and in monitoring disease severity in Parkinson's patients by GPs and specialists in Europe and the US.\nUse of the MANUS Parkinson's pen will provide a more accurate low-cost measure in clinical research and provide a direct cost reduction by assisting with a timely, accurate disease diagnosis to enable early treatment and avoid...